Thermo Fisher Scientific Inc.'s Stock Analysis

Thermo Fisher Issues $3.76 Billion in Senior Notes Offering

Thermo Fisher Scientific Inc. has completed a public offering of senior notes totaling $3.76 billion, comprised of various maturities ranging from 2031 to 2046. The company plans to use the proceeds primarily for the acquisition of Clario Holdings, Inc., along with potential general corporate purposes including debt repayment and capital expenditures.

The notes issued are unsecured obligations and rank equally with existing and future unsecured debt. The terms include provisions for redemption prior to maturity under specific conditions and stipulate that in the event of a change of control, the company may be required to repurchase the notes at a premium. The offering was facilitated through an underwriting agreement with multiple financial institutions.

Feb 12, 2026 16:19:10

Thermo Fisher Scientific Reports Fourth Quarter and Annual Results

Thermo Fisher Scientific announced its financial results for the fourth quarter and full year ended December 31, 2025. In the fourth quarter, the company reported a revenue increase of 7% to $12.21 billion, with GAAP diluted earnings per share (EPS) rising 9% to $5.21. For the full year, revenues grew 4% to $44.56 billion, and GAAP diluted EPS increased 7% to $17.74. The company highlighted its operational performance and product innovations, including several new product launches and strategic collaborations aimed at enhancing its capabilities in drug development and biopharma services.

Thermo Fisher Scientific executed a capital deployment strategy, investing approximately $16.5 billion in 2025, including $13 billion for mergers and acquisitions. Key acquisitions included the Filtration and Separation business from Solventum and a sterile fill-finish site from Sanofi, which expanded its drug product manufacturing capacity. The company also returned $3.6 billion to shareholders through stock buybacks and dividends. The management noted the successful navigation of the external environment and the strengthening of its competitive position as it looks toward future growth.

Jan 29, 2026 06:02:55

Leadership Changes at Thermo Fisher Scientific Announced

Michel Lagarde and Frederick M. Lowery will leave Thermo Fisher Scientific, with Lagarde's departure set for March 31, 2026, and Lowery's for February 28, 2026. These changes are part of a broader organizational update planned for March 1, 2026.

Following the departures, Marc N. Casper will assume the role of Chairman and Chief Executive Officer, while Gianluca Pettiti will be promoted to President and Chief Operating Officer. Michael Shafer will also take on an expanded role and report directly to the CEO starting on the same date.

Jan 12, 2026 06:02:56

Thermo Fisher Scientific Issues €2.1 Billion in Senior Notes

Thermo Fisher Scientific's subsidiary, Thermo Fisher International, has issued €1 billion in Floating Rate Senior Notes due in 2027 and €1.1 billion in Fixed Rate Senior Notes due in 2035. The company has guaranteed these notes and will use the net proceeds, expected to be around €2.09 billion after expenses, for general corporate purposes, including potential acquisitions, debt repayment, and working capital.

The notes rank equally with existing unsecured debt and are senior to subordinated debt. They are subject to certain covenants that restrict the company’s ability to incur secured debt or engage in significant asset sales. In the event of a default, the obligations under the notes may be accelerated, making the entire principal amount due immediately. The company has received legal opinions regarding the securities issued, and the offering was managed by several financial institutions.

Dec 01, 2025 16:15:51

Thermo Fisher to Acquire Clario for $8.875 Billion

Thermo Fisher Scientific has announced a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash, with additional contingent payments based on future performance. The acquisition aims to enhance Thermo Fisher’s capabilities in clinical trial data solutions, which are crucial for pharmaceutical and biotech companies. Clario is expected to generate about $1.25 billion in revenue for the full year 2025 and has supported a significant portion of FDA drug approvals over the past decade. The transaction is anticipated to close by mid-2026, pending regulatory approvals.

The acquisition is projected to be immediately accretive to Thermo Fisher’s adjusted earnings per share and is expected to create synergies that will enhance the company's operating margins. Thermo Fisher plans to finance the transaction through debt and cash on hand. The acquisition aligns with Thermo Fisher’s strategy to expand its digital and data capabilities, ultimately aiming to accelerate drug development processes for its clients in the pharmaceutical and biotech sectors.

Oct 29, 2025 06:05:40

Thermo Fisher Scientific Reports Third Quarter 2025 Financial Results

Thermo Fisher Scientific reported a revenue increase of 5% for the third quarter of 2025, reaching $11.12 billion compared to $10.60 billion in the same quarter of 2024. The company's GAAP diluted earnings per share (EPS) was $4.27, slightly up from $4.25 in the previous year, while adjusted EPS grew by 10% to $5.79. The operational performance was attributed to effective cost management and a strong growth strategy, which included the launch of innovative products and strategic acquisitions in the bioproduction and drug product manufacturing sectors.

The company also highlighted its collaboration with OpenAI to enhance the use of artificial intelligence in its operations and products. Thermo Fisher completed significant acquisitions, including a filtration and separation business and a sterile fill-finish site, and repurchased $1.0 billion in stock during the quarter. The adjusted operating income for the third quarter was $2.59 billion, with an adjusted operating margin of 23.3%, up from 22.3% in the prior year. Updated financial guidance for 2025 was to be provided during the earnings conference call following the report.

Oct 22, 2025 06:05:30

Thermo Fisher Scientific Issues $2.48 Billion in Senior Notes

Thermo Fisher Scientific Inc. issued a total of $2.48 billion in Senior Notes through a public offering. The offering includes four series of notes with varying interest rates and maturities, specifically 4.200% due in 2031, 4.473% due in 2032, 4.794% due in 2035, and 4.894% due in 2037. The interest payments will be made semi-annually, and the company has the option to redeem the notes prior to their maturity dates under certain conditions. The notes are unsecured obligations and rank equally with existing unsecured debt.

The net proceeds from this offering are expected to be approximately $2.48 billion, which will be utilized for general corporate purposes. This may include acquisitions, debt repayment, working capital, capital expenditures, or repurchasing outstanding equity securities. The offering was facilitated by several underwriters, and the notes are subject to certain covenants and potential redemption conditions based on the company's financial status.

Oct 07, 2025 16:30:59

Thermo Fisher Completes $4 Billion Acquisition of Solventum Business

Thermo Fisher Scientific has finalized its acquisition of Solventum Corporation’s purification and filtration business for approximately $4 billion in cash. This newly acquired business will enhance Thermo Fisher's Life Sciences Solutions segment, specifically in the areas of bioprocessing, healthcare, and industrial filtration. The acquisition is expected to generate around $750 million in revenue for the full year 2025 and will contribute advanced filtration technologies aimed at improving quality and efficiency in various industries.

In the first year post-acquisition, Thermo Fisher anticipates a dilution of $0.06 to adjusted earnings per share, but expects to realize significant cost synergies and operational efficiencies over time. The deal is projected to yield approximately $125 million in adjusted operating income from synergies by the fifth year. The acquisition is positioned to drive mid- to high-single digit organic growth, while also expanding Thermo Fisher's reach into markets requiring ultra-pure water, such as battery and semiconductor manufacturing.

Sep 02, 2025 08:03:06

Thermo Fisher Scientific Announces CFO Retirement and Successor

Thermo Fisher Scientific Inc. announced that Stephen Williamson, the Senior Vice President and Chief Financial Officer (CFO), will retire on March 31, 2026. The Board of Directors has approved the appointment of James R. Meyer, currently Vice President of Financial Operations, to succeed Williamson as CFO starting March 1, 2026.

James R. Meyer has been with Thermo Fisher since July 2009, holding various finance positions of increasing responsibility, including Vice President of Finance for Customer Channels from April 2020 to December 2022. He has been in his current role since January 2023 and previously worked at PricewaterhouseCoopers.

Jul 23, 2025 16:16:06

Thermo Fisher Scientific Reports Second Quarter Financial Results

Thermo Fisher Scientific announced its financial results for the second quarter of 2025, reporting revenue of $10.85 billion, a 3% increase from the previous year. GAAP diluted earnings per share (EPS) rose to $4.28, up 6% year-over-year, while adjusted EPS was reported at $5.36. The company highlighted its operational performance, driven by a strong growth strategy and the launch of innovative products designed to enhance scientific research and drug development. Additionally, Thermo Fisher expanded its strategic partnership with Sanofi to acquire a sterile fill-finish site in New Jersey, which is expected to increase U.S. capacity for pharmaceutical production.

In terms of profitability, GAAP operating income for the quarter was $1.83 billion, with an operating margin of 16.9%. The adjusted operating income was $2.38 billion, resulting in an adjusted operating margin of 21.9%. The company plans to provide updated financial guidance for 2025 during its earnings conference call. Thermo Fisher Scientific emphasized its commitment to enabling customer success and adapting to market conditions through its operational strategies.

Jul 23, 2025 06:03:44